Bassem M Mohammed1,2, Qiufang Cheng1, Anton Matafonov1, Ingrid M Verhamme1, Jonas Emsley3, Keith R McCrae4, Owen J T McCarty5,6, Andras Gruber5,6, David Gailani1. 1. Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee. 2. Department of Clinical Pharmacy, School of Pharmacy, Cairo University, Cairo, Egypt. 3. Center for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, UK. 4. Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio. 5. Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, Oregon. 6. Division of Hematology/ Medical Oncology, School of Medicine, Oregon Health & Science University, Portland, Oregon.
Abstract
BACKGROUND: The homologous plasma proteins prekallikrein and factor XI (FXI) circulate as complexes with high molecular weight kininogen. Although evidence supports an interaction between the prekallikrein-kininogen complexes and vascular endothelium, there is conflicting information regarding FXI binding to endothelium. OBJECTIVE: To study the interaction between FXI and blood vessels in mice. METHODS: C57Bl/6 wild-type or F11-/- mice in which variants of FXI were expressed by hydrodynamic tail vein injection, received intravenous infusions of saline, heparin, polyphosphates, protamine, or enzymes that digest glycosaminoglycans (GAGs). Blood was collected after infusion and plasma was analyzed by western blot for FXI. RESULTS AND CONCLUSIONS: Plasma FXI increased 5- to 10-fold in wild-type mice after infusion of heparin, polyphosphates, protamine, or GAG-digesting enzymes, but not saline. Similar treatments resulted in a much smaller change in plasma FXI levels in rats, and infusions of large boluses of heparin did not change FXI levels appreciably in baboons or humans. The releasable FXI fraction was reconstituted in F11-/- mice by expressing murine FXI, but not human FXI. We identified a cluster of basic residues on the apple 4 domain of mouse FXI that is not present in other species. Replacing the basic residues with alanine prevented the interaction of mouse FXI with blood vessels, whereas introducing the basic residues into human FXI allowed it to bind to blood vessels. Most FXI in mice is noncovalently associated with GAGs on blood vessel endothelium and does not circulate in plasma.
BACKGROUND: The homologous plasma proteins prekallikrein and factor XI (FXI) circulate as complexes with high molecular weight kininogen. Although evidence supports an interaction between the prekallikrein-kininogen complexes and vascular endothelium, there is conflicting information regarding FXI binding to endothelium. OBJECTIVE: To study the interaction between FXI and blood vessels in mice. METHODS: C57Bl/6 wild-type or F11-/- mice in which variants of FXI were expressed by hydrodynamic tail vein injection, received intravenous infusions of saline, heparin, polyphosphates, protamine, or enzymes that digest glycosaminoglycans (GAGs). Blood was collected after infusion and plasma was analyzed by western blot for FXI. RESULTS AND CONCLUSIONS: Plasma FXI increased 5- to 10-fold in wild-type mice after infusion of heparin, polyphosphates, protamine, or GAG-digesting enzymes, but not saline. Similar treatments resulted in a much smaller change in plasma FXI levels in rats, and infusions of large boluses of heparin did not change FXI levels appreciably in baboons or humans. The releasable FXI fraction was reconstituted in F11-/- mice by expressing murine FXI, but not human FXI. We identified a cluster of basic residues on the apple 4 domain of mouse FXI that is not present in other species. Replacing the basic residues with alanine prevented the interaction of mouse FXI with blood vessels, whereas introducing the basic residues into human FXI allowed it to bind to blood vessels. Most FXI in mice is noncovalently associated with GAGs on blood vessel endothelium and does not circulate in plasma.
Authors: J C Chan; J G Ganopolsky; I Cornelissen; M A Suckow; M J Sandoval-Cooper; E C Brown; F Noria; D Gailani; E D Rosen; V A Ploplis; F J Castellino Journal: Am J Pathol Date: 2001-02 Impact factor: 4.307
Authors: Tong Gui; Hui-Feng Lin; Da-Yun Jin; Maureane Hoffman; David L Straight; Harold R Roberts; Darrel W Stafford Journal: Blood Date: 2002-07-01 Impact factor: 22.113
Authors: Steven P Grover; Clare M Schmedes; Alyson C Auriemma; Emily Butler; Molly L Parrish; Adam Miszta; Audrey C Cleuren; Mayken Visser; Stefan Heitmeier; Jens J Posma; Henri M Spronk; Silvio Antoniak; Alisa S Wolberg; Rafal Pawlinski; David Gailani; Nigel Mackman Journal: Blood Adv Date: 2020-01-14
Authors: Anh T P Ngo; Kelley R Jordan; Paul A Mueller; Matthew W Hagen; Stéphanie E Reitsma; Cristina Puy; Alexey S Revenko; Christina U Lorentz; Erik I Tucker; Quifang Cheng; Monica T Hinds; Sergio Fazio; Brett P Monia; David Gailani; András Gruber; Hagai Tavori; Owen J T McCarty Journal: J Thromb Haemost Date: 2021-02-10 Impact factor: 5.824